What is ALDX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.06B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALDX?

P/E (TTM) is n/a and 52-week range is $0.86 to $5.93 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALDX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALDX?

The company profile lists net income (TTM) near $-23M, EPS (TTM) near $-0.38 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Aldeyra Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Lexington, Massachusetts, US, 60.3M shares outstanding, ISIN US01438T1060 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Aldeyra Therapeutics Inc

$ALDX

Health Care · Biotechnology

IR Run Scenarios

$0.92

-3.31%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.

Employees

Website

www.aldeyra.com/

IPO

2014-05-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)